You are here

Analysts warn of pitfalls as easy money sparks big M&A boom

Volume in the first nine month totalled US$1.2 trillion, up 89% from the same period last year

Pfizer intends to buy Allergan, which has a market value of over US$110 billion, while Anheuser-Busch InBev is seeking to swallow SABMiller in a deal worth more than US$120 billion when debt is included.


A FLOOD of cheap money is financing the biggest boom in mega-mergers and takeovers since the 2008 global financial crisis. But analysts warn that hastily arranged corporate marriages that seem blissful in good financial times can end in tears, and considerable debts.